Tekmira falls on Ebola data

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a result, the company said enrollment in the study was closed.

Tekmira's TKM-Ebola-Guinea therapy is a combination of short interfering RNAs (siRNAs) targeting the Guinea (Makona) strain of Ebola virus formulated with Tekmira's lipid nanoparticle (LNP) technology. The study's primary endpoint was mortality at 14 days. Tekmira has no other active trials of the therapy. ...